Who makes Drug: Apixaban sprinkle capsules?

Drug: Apixaban sprinkle capsules is developed by Bristol-Myers Squibb.

What development phase is Drug: Apixaban sprinkle capsules in?

Drug: Apixaban sprinkle capsules is in Phase 1.

Last reviewed 2026-05-14 · How we verify

Drug: Apixaban sprinkle capsules

Bristol-Myers Squibb · Phase 1 active Small molecule

At a glance

Generic name	Drug: Apixaban sprinkle capsules
Also known as	•BMS-562247, •Eliquis
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Drug: Apixaban sprinkle capsules CI brief — competitive landscape report
Drug: Apixaban sprinkle capsules updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI